International Journal of Molecular Sciences
August 7, 2023
Alexander Pilozzi, Simmie Foster, David Mischoulon et al.
16 citations
Alzheimer's disease, the most common form of senile dementia, will impose a growing societal and healthcare burden as the population ages. With few treatments for symptomatic relief and unknown causes, more research is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Through microdosing, they may help combat the disease by eliciting psychiatric benefits via serotonin and dopamine pathways. This review examines studied benefits of a few psychedelic compounds that may show promise in treating AD and attenuating its depressive symptoms. The putative mechanism of action is that psychedelics act mainly as serotonin receptor agonists and induce potential beneficial effects for treating AD and related depression.
Journal of personality disorders
April 1, 2025
Albert Yeung, Michael Alpert, David Mischoulon
3 citations
Borderline personality disorder (BPD) involves impulsivity, emotional instability, and perceptual symptoms, and is often complicated by co-occurring conditions like depression. This case study describes ketamine-assisted psychotherapy (KAP) for a patient with both BPD and depression. KAP combines ketamine's antidepressant and psychedelic effects with psychotherapy, relying on the patient's inner healing intelligence and the therapist-patient relationship. Positive outcomes suggest that further systematic research into KAP for BPD and other personality disorders is warranted.
Psychiatry Research Case Reports
May 22, 2026
Albert Yeung, Huiqiong Deng, Wendy Feng et al.
Ketamine-assisted psychotherapy (KAP) may offer a viable treatment for posttraumatic stress disorder (PTSD) in Asian American patients, who face cultural barriers such as stigma and collectivist values that complicate mental health care. In a case study of a 26-year-old Asian American woman with chronic PTSD from childhood abuse and neglect, 11 intramuscular ketamine sessions (mean dose 88.2 mg) over eight months, paired with integration therapy, led to symptom improvement on standardized measures (PCL-5, PHQ-9, GAD-7). The patient's choice to work with an Asian therapist highlighted the importance of cultural concordance. KAP remains understudied in Asian communities.